Connect with us

Business

Shares of Absci protein discovery platform make market debut – TechCrunch

Published

on

 


Absci Corp., a Vancouver-based company behind a multi-faceted drug development platform, went public on Thursday. This is another sign of the growing interest in new approaches to drug development, a traditionally risky business.

Absci focuses on accelerating drug development in preclinical stages. The company has developed and acquired a handful of tools that can predict drug candidates, identify potential drug targets, and test therapeutic proteins on billions of cells and identify those worth pursuing.

We provide a fully integrated, end-to-end solution for pharmaceutical drug development, Absci founder Sean McClain told TechCrunch. Think of it like the Google index search for protein drug discovery and biofabrication.

The IPO was initially priced at $ 16 per share, with a pre-currency valuation of around $ 1.5 billion, by deposit S-1. The company is offering 12.5 million common shares and plans to raise $ 200 million. However, the Absci share has already swelled to$ 21 per share at time of writing. Common shares trade under the symbol ABSI.

The company has chosen to go public now, McClain says, to increase the company’s ability to attract and retain new talent. As we continue to grow and evolve rapidly, we need access to top talent, and the IPO gives us incredible visibility for talent acquisition and retention, said McClain.

Absci was founded in 2011 with a focus on the manufacture of proteins in E. coli. In 2018, the company launched its first commercial product called SoluPro – a bioengineered E. coli system that can build complex proteins. In 2019, the company stepped up this process by implementing a protein printing platform.

Since its inception, Absci has 170 employees and has raised $ 230 million. The most recent inflow was a $ 125 million cross-funding round that closed in June 2020 led by Casdin Capital and Redmile Group. But this year, two major acquisitions completed Abscis’ offering, from protein manufacturing and testing to AI-activated drug development.

In January 2021, Absci acquired Denovium, a company using deep learning AI to categorize and predict protein behavior. The Denoviums engine had been driven on more than 100 million proteins. In June, the company also acquired Totient, a biotechnology company that analyzes the immune system’s response to certain diseases. At the time of the Totient acquisition, the company had already reconstructed 4,500 antibodies gleaned from immune system data from 50,000 patients.

Absci already had protein manufacturing, evaluation and screening capabilities, but the acquisition of Totient enabled it to identify potential targets for new drugs. The Denovium acquisition added an AI-based engine to aid in protein discovery.

What we do now is feed [our own data] in deep learning models and that’s why we acquired Denovium. Before Totient, we were doing drug discovery and cell line development. This [acquisition] allows us to go fully integrated where we can now do target discovery as well, McClain says.

These two acquisitions place Absci in a particularly active niche in the world of drug development.

For starters, there has been notable fiscal interest in developing new drug development approaches, even after decades of poor drug R&D returns. In the first half of 2021, Assess have reported that developers of new drugs have raised $ 9 billion in IPOs on Western Stock Exchanges. This despite the fact that drug development is traditionally high risk. R&D returns for biopharmaceuticals hit a record low of 1.6% in 2019 and rebounded to just around 2.5%, a 2021 Deloitte report notes.

In the world of drug development, we’ve seen AI play an increasingly important role. This same Deloitte report notes that most biopharmaceutical companies are trying to integrate AI into drug discovery and development processes. And, drug discovery projects received the largest amount of AI investment in 2020, according to the Stanford University Artificial Intelligence Index. Annual Report.

More recently, the prospects for using AI in drug development have been bolstered by companies that have taken a candidate through preclinical development stages.

In June, Insilico Medicine, a Hong Kong-based startup, announced that it had brought an AI-identified drug candidate for idiopathic pulmonary fibrosis through the stages of preclinical testing – a feat that helped shut down a $ 255 Million Series C Round. Founder Alexander Zharaonkov told TechCrunch that the PI drug will begin a clinical trial of the drug at the end of this year or early next year.

With a hand in AI and protein manufacturing, Absci has already positioned itself in a crowded space, but filled with hype. But in the future, the company will still have to define the details of its business model.

Absci pursues a business model of partnership with drug manufacturers. This means that the company does not intend to conduct its own clinical trials. Rather, it expects to generate revenue through milestone payments (subject to reaching certain milestones in the drug development process) or, if drugs are approved, royalties on sales.

This offers some advantages, McClain says. The company is able to avoid the risk of drug candidate failure after investing millions of dollars in testing R&D and may invest in the development of hundreds of drug candidates at a time.

At this point, Absci has nine currently active programs with drug manufacturers. The company’s cell line manufacturing platforms are used in drug testing programs at eight biopharmaceutical companies, including Merck, Astellas, and Alpha Cancer Technologies (the rest is undisclosed). Five of those projects are in the preclinical stage, one is in phase 1 clinical trials, one is in phase 3 clinical trial and the last is focused on animal health, according to the company’s S-1 dossier.

One company, Astellas, is currently using the Abscis discovery platforms. But McClain notes that Absci has only just deployed its drug discovery capabilities this year.

However, none of these partners have officially licensed any of the Abscis platforms for clinical or commercial use. McClain notes that the nine active programs have milestones and royalty potentials associated with them.

The company has a long way to go in terms of profitability. So far this year, Absci has generated total revenue of around $ 4.8 million, up from around $ 2.1 million in 2019. Nonetheless, costs have remained high and S-1 records indicate that the company has suffered net losses over the past two years. In 2019, the company reported $ 6.6 million in net losses in 2019 and $ 14.4 million in net losses in 2020.

S-1 Company charges these losses to expenses related to research and development costs, building an intellectual property portfolio, hiring staff, raising capital and supporting these activities.

Absci recently completed construction of a 77,000 square foot facility, McClain notes. Thus, in the future, the company foresees the potential to increase the scale of its operations.

In the immediate future, the company plans to use the money raised during the IPO to increase the number of programs using Abscis technology, invest in R&D, and continue to refine new AI-based products. the society.

Sources

1/ https://Google.com/

2/ https://techcrunch.com/2021/07/22/shares-of-protein-discovery-platform-absci-pop-in-market-debut/

The mention sources can contact us to remove/changing this article

What Are The Main Benefits Of Comparing Car Insurance Quotes Online

LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos

ExBUlletin

to request, modification Contact us at Here or [email protected]